Market Overview

UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential

Share:
Related
Discussing Snoop Dogg's Marijuana-Focused VC Firm: 'Beyond Wearing The Investor Hat, We Differentiate With A Broad Internal Ecosystem'
Nevada Marijuana Emergency Shows The Real Size Of America's Demand For Cannabis
Fed, FANGs, Autos, Defense, Eateries On Deck: Investing Action Plan (Investor's Business Daily)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), but lowered the price target from $54.00 to $51.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

AbbVie closed on Thursday at $43.04.

Latest Ratings for ABBV

DateFirmActionFromTo
Jul 2017Deutsche BankMaintainsHold
Jul 2017JefferiesMaintainsBuy
Mar 2017Goldman SachsMaintainsBuyBuy

View More Analyst Ratings for ABBV
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABBV)

View Comments and Join the Discussion!